Saltar al contenido
Merck

Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.

Journal of neurophysiology (2012-12-12)
Jessica M D'Amico, Katherine C Murray, Yaqing Li, K Ming Chan, Mark G Finlay, David J Bennett, Monica A Gorassini
RESUMEN

In animals, the recovery of motoneuron excitability in the months following a complete spinal cord injury is mediated, in part, by increases in constitutive serotonin (5-HT2) and norepinephrine (α1) receptor activity, which facilitates the reactivation of calcium-mediated persistent inward currents (CaPICs) without the ligands serotonin and norepinephrine below the injury. In this study we sought evidence for a similar role of constitutive monoamine receptor activity in the development of spasticity in human spinal cord injury. In chronically injured participants with partially preserved sensory and motor function, the serotonin reuptake inhibitor citalopram facilitated long-lasting reflex responses (spasms) previously shown to be mediated by CaPICs, suggesting that in incomplete spinal cord injury, functional descending sources of monoamines are present to activate monoamine receptors below the lesion. However, in participants with motor or motor/sensory complete injuries, the inverse agonist cyproheptadine, which blocks both ligand and constitutive 5-HT2/α1 receptor activity, decreased long-lasting reflexes, whereas the neutral antagonist chlorpromazine, which only blocks ligand activation of these receptors, had no effect. When tested in noninjured control participants having functional descending sources of monoamines, chlorpromazine was effective in reducing CaPIC-mediated motor unit activity. On the basis of these combined results, it appears that in severe spinal cord injury, facilitation of persistent inward currents and muscle spasms is mainly mediated by the activation of constitutive 5-HT2 and α1 receptor activity. Drugs that more selectively block these constitutively active monoamine receptors may provide better oral control of spasticity, especially in motor complete spinal cord injury where reducing motoneuron excitability is the primary goal.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Chlorpromazine hydrochloride, ≥98% (TLC)
Supelco
Chlorpromazine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Chlorpromazine hydrochloride, meets USP testing specifications
Supelco
Chlorpromazine hydrochloride, VETRANAL®, analytical standard
Chlorpromazine hydrochloride, European Pharmacopoeia (EP) Reference Standard